Adrian Bracken
@adrianbracken.bsky.social
Epigenetics & Chromatin Biology | Polycombs in Development & Disease | Cancer Genetics | Professor of Chromatin Biology, Trinity College Dublin | www.brackenlab.com
Have you started planning your Autumn conference calendar yet?🍂 The programme is now LIVE for the 5th edition of our #FusionEpigenetics meeting Discover our latest speaker talk titles, short talk selections, and exciting networking opportunities here: bit.ly/4dSjjr8
📅 Webinar reminder! Join us this Friday for @kjarmache.bsky.social webinar. More details below, or you can register here for free: us06web.zoom.us/webinar/regi... @activemotifusa.bsky.social
All-Ireland Chromatin Consortium@aicc-ireland.bsky.social · 4mo agoHands up if you love chromatin & structural biology 🙋♂️ On Friday April 24th we will be joined by @kjarmache.bsky.social from NYU for his webinar 'Chromatin-Modifying Complexes in Gene Activation and Silencing'. Register here: us06web.zoom.us/webinar/regi... @activemotifusa.bsky.social
Hands up if you love chromatin & structural biology 🙋♂️ On Friday April 24th we will be joined by @kjarmache.bsky.social from NYU for his webinar 'Chromatin-Modifying Complexes in Gene Activation and Silencing'. Register here: us06web.zoom.us/webinar/regi... @activemotifusa.bsky.social
⏰ Calling all chromatin aficionados! We we will be joined by @adelmanlab.bsky.social from @harvardmed.bsky.social for our March 27th webinar 📅 Karen will be sharing her groups work on 'Transcription & RNA Quality Control in Health & Disease' 😷🧬 Register here: us06web.zoom.us/webinar/regi...
Only 24 hours to go to our next webinar with @brianstrahl.bsky.social ! Make sure to register for free through link below 👇
All-Ireland Chromatin Consortium@aicc-ireland.bsky.social · 6mo agoWebinar reminder ⏰ Next Friday join us for @brianstrahl.bsky.social - from @uncchapelhill.bsky.social - webinar on 'Chromatin at the Crossroads of Gene Regulation and Genome Integrity'. Don't miss out! See registration details below! us06web.zoom.us/webinar/regi... @activemotifusa.bsky.social
We are delighted to launch the (free!) registration for our 5th AICC symposium, hosted this year in @ucddublin.bsky.social on May 27th. If you are interested in chromatin, gene regulation or the nucleus please join us! allirelandchromatinconsortium.ie/annual-meeti...
Just one week to go until Edith Heard will be joining us for the All-Ireland Chromatin Consortium webinar on 'The Epigenetic Dynamics of X Inactivation in Development and Disease' 🧬 Registration link: us06web.zoom.us/webinar/regi...
Welcome! You are invited to join a webinar: All Ireland Chromatin Consortium February 2026 - Edith Heard. After registering, you will receive a confirmation email about joining the webinar.
The All-Ireland Chromatin Consortium was established in 2021 to foster collaborations between researchers located across the whole of Ireland, promote scientific exchange, and to facilitate networking...
us06web.zoom.us
All-Ireland Chromatin Consortium@aicc-ireland.bsky.social · 7mo agoAfter a short break in our webinars we are delighted to be back up & running this month! First up, on Jan 30th we will be joined by @lucas.farnunglab.com from @harvardmed.bsky.social 🔬 Shortly after, on Feb 13th we will be hosting @heardlab.bsky.social from @crick.ac.uk 🧬 Registration details 👇
@adrianbracken.bsky.social we are looking forward to your presentation at our #FusionEpigenetics meeting in Portugal this October! Please share this with your followers to let them know you will speaking, and to register & submit today to join us 🔗 bit.ly/4rC6B45
Synovial sarcoma is driven almost exclusively by a single oncofusion – SS18-SSX For years, the assumptions on disease mechanisms were simple: ➡️ SS18-SSX works by hijacking SWI/SNF chromatin remodeling activity Our new study shows that assumption was wrong 🧵👇 www.biorxiv.org/content/10.6...
SS18-SSX co-opts P300 to sustain oncogenic transcription independent of SWI/SNF activity
Synovial sarcoma is driven by the SS18-SSX fusion oncoprotein, which has been assumed to promote tumorigenesis through its incorporation into the SWI/SNF chromatin remodeling complexes. Accordingly, therapeutic efforts have focused on targeting SS18-SSX containing SWI/SNF assemblies, yet these approaches have produced limited clinical benefit. Here, we demonstrate that SS18-SSX sustains oncogenic transcription independent of SWI/SNF activity. Despite efficient degradation and dismantling of SWI/SNF complexes, fusion occupancy at target loci and associated gene expression programs remain largely intact. Instead, we identify the acetyltransferase P300 as an essential co-factor supporting SS18-SSX chromatin binding and transcriptional activation. Targeting P300 displaces the fusion from chromatin, suppresses its transcriptional output, compromising synovial sarcoma viability. Notably, dual PROTAC mediated degradation of P300 and SWI/SNF produces strong synergistic effects, broadly disrupting SS18-SSX localization and function. These findings redefine the mechanistic basis of synovial sarcoma and reveal a mechanistically anchored therapeutic strategy for targeting its core oncogenic driver. ### Competing Interest Statement C.R.V. has been a consultant for Flare Therapeutics, Roivant Sciences and C4 Therapeutics; has served on the advisory boards of KSQ Therapeutics, Syros Pharmaceuticals and Treeline Biosciences; has received research funding from Boehringer Ingelheim and Treeline Biosciences; and owns stock in Treeline Biosciences. S.A.A. has been a consultant and/or shareholder for Neomorph, Imago Biosciences, Hyku Therapeutics, C4 Therapeutics, Accent Therapeutics and Nimbus Therapeutics; and has received research support from Janssen and Syndax. N.O.C. is a co-founder, shareholder and management consultant for PhenoTherapeutics Ltd; and a shareholder in Amplia Therapeutics Ltd All other authors declare no financial interests UKRI, EP/X039633/1 Worldwide Cancer Research, https://ror.org/031tfbz57, 21-0271 Science Foundation Ireland, https://ror.org/0271asj38, 18/SIRG/5573
biorxiv.org
After a short break in our webinars we are delighted to be back up & running this month! First up, on Jan 30th we will be joined by @lucas.farnunglab.com from @harvardmed.bsky.social 🔬 Shortly after, on Feb 13th we will be hosting @heardlab.bsky.social from @crick.ac.uk 🧬 Registration details 👇
Two alternative isoforms of PRC2 accessory subunit AEBP2 modulate developmental Polycomb functions in opposite ways - with broadly-expressed AEBP2L acting as an intrinsic inhibitor in somatic cells @adrianbracken.bsky.social @davidovichlab.bsky.social and colleagues www.embopress.org/doi/full/10....
We are delighted that @genesdev.bsky.social have selected our (w/ @adrianbracken.bsky.social) Weaver syndrome paper artwork as the November cover! This piece was made by my incredibly talented niece, Gina 'Dna Vinci' Ronan. @ucddublin.bsky.social @tcddublin.bsky.social @ucd-sbbs.bsky.social
Genes & Development@genesdev.bsky.social · 9mo ago🚨 NEW ISSUE ALERT!!! 🚨 New Outlook, Review and Research articles online now at Genes & Development. Click on the link to learn more: ➡️ https://genesdev.cshlp.org/content/39/21-22.toc
1/ 🚀 AEBP2 isn’t what we thought. You were told that AEBP2 promotes PRC2 activity on chromatin. We found the opposite: the most prevalent AEBP2 isoform inhibits PRC2 activity. 👉 surl.li/cgwqcq A thread 🧵
Absolutely delighted to share our preprint, using functional genomics to uncover a novel dependency in lymphoma that can overcome resistance to targeted therapy. Grateful to co-first author @jamesnolan.bsky.social and co-senior authors @conwayer1.bsky.social and @adrianbracken.bsky.social see👇
James Nolan@jamesnolan.bsky.social · 10mo ago🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇 #CancerResearch #Epigenetics #Chromatin #Lymphoma
🧵1/Exciting news in cancer epigenetics! Our latest research, "AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma", is now available on www.biorxiv.org/content/10.1.... Here's a thread summarizing our findings!👇 #CancerResearch #Epigenetics #Chromatin #Lymphoma
AEBP2-Directed H3K27me2 Defines a Specific Vulnerability in EZH2-mutant Lymphoma
The catalytic subunit of Polycomb Repressive Complex 2 (PRC2), EZH2, is recurrently mutated in 25% of diffuse large B-cell lymphomas (DLBCL), causing increased H3K27me3 and decreased H3K27me2 levels. ...
biorxiv.org
2/ Firstly, this was a fantastic collaborative effort that would not have been possible without super-talented co-first author @dr-chromatin.bsky.social, and co-senior authors @conwayer1.bsky.social and @adrianbracken.bsky.social.
Delighted that our work on EZH2 dominant negativity in Weaver syndrome is now out in Genes & Development! This exciting work on chromatinopathies 🧬 was in collab with @adrianbracken.bsky.social and spearheaded by Orla Deevy. @ucddublin.bsky.social @ucd-sbbs.bsky.social www.ucd.ie/newsandopini...
UCD co-lead breakthrough discovering genetic mechanism driving Weaver syndrome
ucd.ie
Check out this 🧵 from @eimearlagan.bsky.social on our new Molecular Cell @cp-molcell.bsky.social paper! We show how the H3K27M Oncohistone reprograms chromatin in DMG, creating a specific dependency on CBX4/PCGF4-containing forms of cPRC1 👇
Eimear Lagan@eimearlagan.bsky.social · last yr.Excited to share our new paper out today in @cp-molcell.bsky.social! We show that the H3K27M oncohistone rewires cPRC1, creating a unique dependency on CBX4/PCGF4-containing complexes, and also reveal a previously unknown function of CBX4. Highlights below (1/11).
🧬🧪Exciting chromatin research conference hosted by @aicc-ireland.bsky.social in May! The deadline for poster/talk abstracts is April 28, see details in the post below.
All-Ireland Chromatin Consortium@aicc-ireland.bsky.social · last yr.We are very excited to launch the registration for our 2025 symposium on 'Chromatin, Epigenetics and Transcription' today! Join us at @tcddublin.bsky.social on May 28th for this event featuring keynote, new PI and PhD/postdoc talks and posters! allirelandchromatinconsortium.ie/annual-meeti...
We are very excited to launch the registration for our 2025 symposium on 'Chromatin, Epigenetics and Transcription' today! Join us at @tcddublin.bsky.social on May 28th for this event featuring keynote, new PI and PhD/postdoc talks and posters! allirelandchromatinconsortium.ie/annual-meeti...
1/ H3K27me3 mimicry has repeatedly emerged through evolution, but what's the physiological relevance? We show that JARID2 and PALI1 mimic H3K27me3 to antagonise PRC2 in vivo and restrict the spread of Polycomb domains. 🧵 www.biorxiv.org/content/10.1...
Looking forward to welcoming @peterlewislab.bsky.social from @uwmadison.bsky.social for our March webinar on 'Dissecting the Biochemical Complexes Governing Gene Silencing' on March 28th! Register here: us06web.zoom.us/webinar/regi... @activemotifusa.bsky.social
What a week it has been for our @uniofgalway.bsky.social committee members @jgahan.bsky.social and @thecocodium.bsky.social. Congrats on the grant successes from @researchireland.bsky.social and @wellcometrust.bsky.social respectively! Keep an eye out for job ads from them soon 👀
James Gahan@jgahan.bsky.social · last yr.More great news! The CCB is on fire at the moment. If you are looking for opportunities to join a successful (and friendly) group of Chromosome biologists, either as a PhD/Postdoc or group leader, then get in touch: chromosome.ie
Coming up this month on Feb 28th- we will be joined by @arnausebe.bsky.social from the @crg.eu for his webinar on 'The origin and early evolution of animal regulatory genome architecture'. Registration details here: us06web.zoom.us/webinar/regi... @activemotifusa.bsky.social
Just a few days left to submit your abstract for our #Epigenetics2025 conference in Belfast! genetics.org.uk/events/epige...
Join us in Belfast for our #epigenetics meeting and hear from fantastic speakers. Submit an abstract until 26 Jan and register until 23 Feb! Don't miss this chance to share your research & network with experts in the field. genetics.org.uk/events/epige...
Epigenetics-2025, from mechanisms to disease | Genetics Society
Meeting background This international conference will bring together leading experts to foster dynamic discussions on the latest breakthroughs in epigenetics. It will cover mechanisms of epigenetic re...
genetics.org.uk
Congratulations to all authors on this very interesting work! Regarding EZH1, it aligns well with what our group and Danny Reinberg's group have proposed based on structural and functional data.
Adrian Bracken@adrianbracken.bsky.social · 2y agoPlease see 🧵by @evhealy.bsky.social about our new paper exploring the role of PRC1 and PRC2 in non-dividing cells 👇
Please see 🧵by @evhealy.bsky.social about our new paper exploring the role of PRC1 and PRC2 in non-dividing cells 👇
Evan Healy@evhealy.bsky.social · 2y ago🧵 1/ We’re excited to share that our new paper with @adrianbracken.bsky.social lab is out 🎉 In this study (which began over 10 years ago!), we explore the biology of PRC2 and PRC1 in non-dividing cells. We also explore the effects of PRC2 inhibitor drugs on these cells. Here’s what we found👇
Our first 2025 webinar is coming up in a few weeks - Jan 31st! Mark your calendars! @davidlabmsk.bsky.social will join us for her webinar on 'Turning back the clock: Targeting a new metabolism-epigenetic axis in T-cells.' Registration: us06web.zoom.us/webinar/regi... @activemotifusa.bsky.social
